Investigation Report on Chinese Insulin Glargine Market, 2018-2022
|発行||China Research and Intelligence||商品コード||674762|
|出版日||ページ情報||英文 30 Pages
|インスリングラルギンの中国市場の分析 Investigation Report on Chinese Insulin Glargine Market, 2018-2022|
|出版日: 2018年08月06日||ページ情報: 英文 30 Pages||
With the development of China's economy, the improvement of residents' living standard, the change of lifestyle and the aging of population, diabetes is seeing a rising prevalence and has become the third most serious chronic disease that threatens human health next to tumors and cardiovascular diseases.
According to WHO's data, there are about 110 million diabetics in China, about 1/10 of China's adults. And the number will increase to 150 million in 2040 if no swift actions are taken to reduce the risk factors such as unhealthy diet and lack of exercises. The rapid growth of diabetes has placed a heavy burden on China's social and economic development.
Insulin Glargine is the first long-acting insulin produced by simulating recombinant DNA technology. It was approved to be put into use by FDA in Apr. 2000 and then by the European Agency for the Evaluation of Medicinal Products (EMEA) in Jun. 2000. The sales value has been growing since Insulin Glargine entered China and exceeded CNY 800 million in 2017.
In China, the third generation of insulin is still under promotion. Due to the relatively high price, it has not yet dominated the market. The second and third generations of insulin will form a market pattern of dislocation competition.
Because Insulin Glargine is mainly produced by genetic engineering methods, the threshold of production technology is relatively high. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap. Hence manufacturers must attain an industrial production of large scale, low cost and mature technology to gain profits. At present, the Chinese market is dominated by Aventis Behring's brand-name drug and the generic drugs of Gan & Lee Pharmaceuticals and Zhuhai United Laboratories Co., Ltd. However, it is expected that the market pattern in China will change in the next few years as some domestic enterprises are speeding up the development of generic Lantus.
According to CRI, the incidence of diabetes keeps increasing in China with the improvement of people's living standard and the change of lifestyle, which expands the diabetes drug market year by year. The market size of diabetes drugs in China exceeded CNY 30 billion in 2017. The third-generation insulin products have been technically improved, reduced some shortcomings of the second-generation products, and effectively shortened the treatment time. They are expected to completely replace the second-generation insulin in the future. It is foreseeable that Insulin Glargine is the product with most growth potential among the three generations of insulin products in China, and its market size will continue to grow from 2018 to 2022.